Content
01/04/2024
South San Francisco, CA USA
Human Immunology Biosciences
completed $95 million Series B Round funding. Investors include
Alpha Wave Global (lead), Viking Global Investors, Jeito Capital, Arkin Bio Ventures, ARCH Venture Partners.
About
Human Immunology Biosciences (HI-Bio) is leading clinical immunology into its next chapter with therapies that target cellular drivers of disease. HI-Bio uses a precision medicine approach to deliver therapies for patients with the auto-immune, allergic and inflammatory diseases that can together be referred to as immune-mediated diseases (IMDs).
Startup
Human Immunology Biosciences
https://www.hibio.com
Claim Profile
Location:
South San Francisco, CA USA
Sector:
Biotech
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
